Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients
We demonstrated the development of MLE Myomedins specifically recognizing hPD-L1 that may serve as a refinement tool for clinical PD-L1 detection.
Authors
- Jana Vaculová (ORCID: https://orcid.org/0000-0002-9493-6365)
- Prosenjit Chakraborty (ORCID: https://orcid.org/0000-0002-2435-9582)
- Petr Malý (ORCID: https://orcid.org/0000-0001-8118-0581)
- Milan Kuchař
- Hana Petroková (ORCID: https://orcid.org/0000-0002-8243-320X)
- Leona Rašková Kafková (ORCID: https://orcid.org/0000-0002-2016-1886)
- Joanna Maria Mierzwicka
- Milan Raška (ORCID: https://orcid.org/0000-0002-8572-7246)
- Petr Kosztyu
- Jozef Škarda (ORCID: https://orcid.org/0000-0003-3579-3066)
- Ondřej Fischer
Institutions
- University Hospital Ostrava (CZ)
- Czech Academy of Sciences, Institute of Biotechnology (CZ)
- University Hospital Olomouc (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1186/s12967-025-06699-6
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- European Commission
- Ministerstvo Školství, Mládeže a Tělovýchovy